TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival by E. Lesma et al.
TSC2 epigenetic defect in primary LAM cells. Evidence of an
anchorage-independent survival
Elena Lesma a, #, *, Silvia Ancona a, #, Silvia M. Sirchia b, Emanuela Orpianesi a, Vera Grande a,
Patrizia Colapietro b, Eloisa Chiaramonte a, Anna Maria Di Giulio a, Alfredo Gorio a
a Laboratory of Pharmacology, Dept. of Health Sciences, Universita degli Studi di Milano, Milano, Italy
b Laboratory of Medical Genetics, Dept. of Health Sciences, Universita degli Studi di Milano, Milano, Italy
Received: July 25, 2013; Accepted: December 18, 2013
Abstract
Tuberous sclerosis complex (TSC) is caused by mutations in TSC1 or TSC2 genes. Lymphangioleiomyomatosis (LAM) can be sporadic or asso-
ciated with TSC and is characterized by widespread pulmonary proliferation of abnormal a-smooth muscle (ASM)-like cells. We investigated the
features of ASM cells isolated from chylous thorax of a patient affected by LAM associated with TSC, named LAM/TSC cells, bearing a germline
TSC2 mutation and an epigenetic defect causing the absence of tuberin. Proliferation of LAM/TSC cells is epidermal growth factor (EGF)-depen-
dent and blockade of EGF receptor causes cell death as we previously showed in cells lacking tuberin. LAM/TSC cells spontaneously detach
probably for the inactivation of the focal adhesion kinase (FAK)/Akt/mTOR pathway and display the ability to survive independently from adhe-
sion. Non-adherent LAM/TSC cells show an extremely low proliferation rate consistent with tumour stem-cell characteristics. Moreover, LAM/
TSC cells bear characteristics of stemness and secrete high amount of interleukin (IL)-6 and IL-8. Anti-EGF receptor antibodies and rapamycin
affect proliferation and viability of non-adherent cells. In conclusion, the understanding of LAM/TSC cell features is important in the assessment
of cell invasiveness in LAM and TSC and should provide a useful model to test therapeutic approaches aimed at controlling their migratory ability.
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Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder
caused by inactivating mutations in TSC1 or TSC2 genes encoding
hamartin and tuberin respectively [1–3]. The outcome of such genetic
alterations is a multisystem disorder exhibiting a wide range of mani-
festations characterized by tumour-like lesions called hamartomas in
various organs and pulmonary lymphangioleiomyomatosis (LAM)
that may occur in association with TSC or sporadically [4, 5]. Lym-
phangioleiomyomatosis is characterized by alveolar smooth muscle
cell proliferation, and cystic destruction of lung parenchyma causing
recurrent pneumothorax, dyspnoea and respiratory failure [6]. Identi-
cal TSC2 mutations and loss of heterozygosity (LOH) patterns were
found in LAM cells from lung nodules, angiomyolipomas (AMLs) and
lymph nodes of the same sporadic LAM patient, suggesting that the
two diseases share a common genetic origin; this is also consistent
with metastatic spread among organs [7, 8]. Furthermore, LAM cells
were identified in donor lungs after transplantation and could be iso-
lated from blood, urine and chylous effusion of patients with LAM
[8, 9]. Such behaviour of LAM cells with respect to their infiltrative
growth pattern, metastatic potential and altered cell differentiation is
reminiscent of cells undergoing epithelial-to-mesenchymal transition
(EMT) [10].
The focal and variable nature of the hamartomas seen in TSC have
long suggested that these tumours may develop following the two-hit
model originally proposed for retinoblastoma by Knudson [11]. Loss
of heterozygosity in TSC1 or TSC2 has been documented in LAM
cells, in AMLs, and purified AML cells, in cardiac rhabdomyomas of
patients, but it has only rarely been found in cerebral cortical tubers
and skin lesions [12, 13]. The inability to find a second somatic event
in TSC lesions has been attributed to either different genetic and epi-
genetic alterations in TSC genes or cell heterogeneity in TSC hamarto-
mas [14, 15]. The absence of tuberin in smooth muscle-like cells
from AML of a TSC2 patient caused by methylation of the TSC2 pro-
moter was recently described [16]. DNA methylation is an epigenetic
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change that induces chromatin modifications and repression of tran-
scription via a methyl CpG binding proteins, and recruitment of a co-
repressor complexes [17, 18].
Here, from chylous effusion of a LAM/TSC patient, we report the
isolation and characterization of a homogenous population of
a-smooth muscle-like (ASM) cells with absence of tuberin for a TSC2
mutation of one allele and an epigenetic alteration of the second allele.
The proliferation of these cells was epidermal growth factor (EGF)-
dependent and the blockade of EGF receptor (EGFR) caused cell death
as we previously reported for tuberin null cells [16, 19]. We studied
the LAM/TSC cells’ ability to survive independently from the anchor-
age and to switch from adherent to a non-adherent status. Rapamycin
and anti-EGFR antibodies caused reduction in cell growth and
decreased anchorage-dependent survival. LAM/TSC cells secrete high
amount of interleukin (IL)-6 and IL-8, cytokines with a crucial func-
tional role in a variety of cancer cells [20].
Materials and methods
Cell cultures, treatments and proliferation assay
Chylous was obtained from a patient affected by LAM associated with
TSC who had given her informed consent according to the Declaration
of Helsinki. The study was approved by the Institutional Review Board
of Milan’s San Paolo Hospital. Chylous was centrifuged and pellet
repeatedly washed in PBS. Pellet was resuspended in Type II complete
medium (50/50 mixture of DMEM/Ham F12; Euroclone, Paignton, United
Kingdom) supplemented with 2.5 lg/ml hydrocortisone (Sigma-Aldrich,
St. Louis, MO, USA), 10 ng/ml EGF (Sigma-Aldrich), 8.6 ng/ml sodium
selenite (Sigma-Aldrich), 25 lg/ml insulin (Sigma-Aldrich), 10 lg/ml
transferrin (Sigma-Aldrich), 0.445 lg/ml ferrous sulphate (Sigma-
Aldrich) and 15% foetal bovine serum (FBS) (Euroclone) [19, 21].
LAM/TSC cells were used between passage 5 and 15. TSC2/ and
TSC2/meth ASM cells were isolated from AMLs of a female and male
TSC2 patients respectively [16, 19]. TSC2/ ASM cells are character-
ized by a germline TSC2 exon 18 mutation consisting of a base pair
change in amino acid 698 from a lysine to a stop codon (K698X) and a
deletion (LOH) of the TSC2 second allele [19]. TSC2/meth ASM cells
are characterized by a germline TSC2 intron 8-exon nine junction muta-
tion (c.867-2A>G) and an epigenetic silencing of the second allele
caused by promoter methylation [16]. TSC2/ and TSC2/meth ASM
cells were grown in Type II complete medium with 15% FBS. Human
aortic smooth muscle cells (HASMCs; Invitrogen, Carlsbad, CA, USA)
were maintained in F12 medium with 10% FBS. COS7 (fibroblast-like
cells; ATCC, Manassas, VA, USA), MCF7 (breast cancer cells; ATCC)
and human mammary epithelial cells (HMECs; ATCC) were maintained
in DMEM containing 10% FBS.
Proliferation was assayed in a Neubauer chamber in the presence or
absence of EGF (10 ng/ml), after incubation with anti-EGFR antibody
Ab3 (clone 225; Calbiochem, Darmstadt, Germany) or anti-EGFR anti-
body Ab5 (EGFR.1; Calbiochem) at the concentration of 5 lg/ml, and
rapamycin at the concentration of 1 or 5 ng/ml (Rapamune-Sirolimus,
Wyeth Europa, United Kingdom). Trichostatin A (Sigma-Aldrich) was
incubated for 72 hrs (1 ng/ll), 5-azacytidine (Sigma-Aldrich) for 96 hrs
(0.24 ng/ll) and PF-537228 (PF228; Sigma-Aldrich) for 8 hrs (0.5 and
5 ng/ll).
Cell immunofluorescence microscopy
The cells, cultured on glass slides and permeabilized with Cytoskelfix
(Cytoskeleton, Denver, CO, USA), were incubated overnight at 4°C
with the primary antibodies (Table 1). Samples were incubated for
3 hrs at room temperature with Alexa 488- or Alexa 555-conjugated
secondary antibody (Invitrogen). The fluorescence of the cells was
analysed by using a laser scanning confocal microscope (LEICA
DMIRE2, Wetzlar, Germany). Nuclei were stained with DAPI (2 lg/ml;
Sigma-Aldrich).
Table 1 List and dilution of primary antibodies
Primary antibodies Dilution Supplier
a-actin 1:100 Sigma-Aldrich
HMB45 1:100 DAKO
CD44v6 1:100 Invitrogen
Hamartin 1:100 Santa Cruz
Tuberin (carboxy-terminus) 1:1000 Cell Signaling
Tuberin (amino-terminus) 1:1000 Cell Signaling
Phospho-tuberin
(Thr1462)
1:1000 Cell Signaling
E-Cadherin 1:50 BD
Phospho-S6 ribosomal
protein (Ser235/236)
1:1000 Cell Signaling
S6 ribosomal protein 1:1000 Cell Signaling
Phospho-Erk
(Thr202/Tyr204)
1:1000 Cell Signaling
Erk 1.1000 Cell Signaling
Phospho-Akt (Ser473) 1:1000 Cell Signaling
Phospho-mTOR (Ser2448) 1:1000 Cell Signaling
Phospho-mTOR (Ser2481) 1:1000 Cell Signaling
Vimentin 1:1000 Cell Signaling
SNAIL 1:1000 Cell Signaling
Phospho-FAK (Tyr397) 1:100 Santa Cruz
Cdk4 1:100 Santa Cruz
Cyclin D1 1:100 Santa Cruz
PCNA 1:250 Chemicon
b-actin 1:1000 Sigma-Aldrich
DAKO, Carpinteria, CA, USA; Santa Cruz Biotechnology, Santa Cruz,
CA, USA; Cell Signaling, Beverly, CA, USA; Chemicon, Temecula, CA,
USA; BD Bioscience, San Jose`, CA, USA.
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Western blotting
Cells were lysed in lysis buffer (1.9 mg/ml ethylenediaminetetraacetic
acid, 8.2 mg/ml deoxycholic acid, 3% SDS), electrophoretically run on a
10% sodium SDS-PAGE and transferred to nitrocellulose membranes
(Amersham, Arlington Heights, IL, USA). After being blocked at room
temperature for 1 hr with 5% dry milk (Merck Millipore, Darmstadt,
Germany), membranes were incubated overnight at 4°C with primary
antibodies (Table 1). The membranes were incubated for 1 hr with sec-
ondary antibodies (1:10,000) horseradish peroxidase conjugated (Pierce,
Rockford, IL, USA). The reaction was revealed by using the SuperSignal
West Pico chemiluminescent substrate (Pierce). Images were acquired
on a Kodak image station 440 CF. Densitometric analysis was per-
formed by using Kodak MJ project program (Kodak, Milan, Italy) and
results were expressed as the mean value from at least three indepen-
dent experiments relatively to b-actin levels.
Mutation study and LOH analysis
DNAs were extracted from cultured cells by using the Wizard Genomic
DNA purification kit (Promega, Madison, WI, USA). All of the exons and
intron-exons junctions of TSC1 and TSC2 from the genomic DNAs were
amplified by means of standard PCR and described primers [22]. The
sequencing reactions were performed as previously reported by Lesma
et al. [16]. Loss of heterozygosity was analysed as previously described
in Lesma et al. [16].
Pyrosequencing analysis
To quantify the methylation levels of TSC2 promoter, pyrosequencing
technology was used to analyse the TSC2 CpG island (CpG 94,
chr16:2097466-2098365, UCSC Genome Browser). DNA conversion and
PCR reaction were carried out as previously described [23] by using
the primers and conditions described in Table 2. The analysed
sequences are shown in Figure 2. Pyrosequencing reactions were per-
formed as previously described in Sirchia et al., [24]. To assess the
methylation pattern in normal condition, we analysed different normal
DNA from peripheral blood lymphocytes.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assay was performed with the ChIP
assay kit (Merck Millipore) by using anti-AcH3, anti-H3 lysine 4 trime-
thylation (H3TrimK4) and anti-H3 lysine 9 trimethylation (H3TrimK9)
antibodies (Merck Millipore), according to the manufacturers’ instruc-
tions. Chromatin was immunoprecipitated from 1 to 3 9 106 cells, to
work in saturating conditions for each antibody. Chromatin fractions
obtained by immunoprecipitation were purified by using QIAquick PCR
purification kit (Qiagen, Hilden, Germany), following the manufacturer’s
instructions. Quantification of the TSC2 promoter region in chromatin
fractions was performed by TaqMan-Real Time PCR by using primers F:
5′-GTCAGCTGGGCTGTAGTTGAGTT-3′ and R: 5′-TCTGGTGGGCATA
ACCTTTCC-3′ and TaqMan probe 6FAM- CCCAGGGAGTGTGGG. The Taq-
Man assay was designed by using Primer Express 3.0 Software
(Applied Biosystems, Foster, CA, USA). All experiments were performed
by using StepOneTM Real-Time PCR System with Fast protocol, using
TaqMan Fast Universal PCR Master Mix (29), No AmpErase UNG
(Applied Biosystems) on StepOneTM Real-Time PCR System. The amount
of TSC2 promoter was calculated by using the 2DDCt method relative
to INPUT sample (chromatin before immunoprecipitation). Background
(negative control without antibody) was subtracted from all samples. To
assess the normal chromatin pattern, we analysed HMECs.
Trypan blue exclusion assay
Quantification of viable cells was performed by incubating the cells in
trypan blue staining solution (1:25; Sigma-Aldrich) for 8 min. at room
temperature. Cells were counted in Neubauer chamber. Results repre-
sent the number of viable cells over the total number of cells counted.
Anchorage-independent growth assay
105 cells of adherent LAM/TSC cells and HASMC were plated. Plates
were prepared as follows: 2% agarose solution was mixed with an equal
volume of Type II Complete Medium and poured onto 35 mm petri
dish, forming an agarose base. Then, a 0.6% agarose solution was
mixed with an equal volume of Type II Complete Medium containing the
Table 2 Conditions and primers sequences for pyrosequencing assay
Method Primer sequences Annealing Nr of CpG investigated
PCR 1 F1 5′-TTYGTTAGAGGGYGGTATAGAAT-3′
R1 5′-bio ACACTACRAAATCCRCCTCTC-3′
52°C
Pyrosequencing 1 S1 5′-ATYGGAAGTGYGGGT-3′ 10
PCR 2 F2 5′-GGAAGYGTTTTTTTGTTTGG-3′
R2 5′-bio CCRCRCCRTAACTAACTAAAACRTA-3′
55°C
Pyrosequencing 2 and 3 S2 5′-GGYGAAAGGGGGTAG-3′
S3 5′-TGTAATTTTTGGGAAAAAG-3′
6
8
PCR 3 F3 5′-TAYGTTTTAGTTAYGGYGYGG-3′
R3 5′-bio ATAATTCTATACCRCCCTCTA-3′
54°C
Pyrosequencing 4 S4 5′-GGTTAGTATTTT-3′ 4
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cell suspension producing a 0.3% agarose solution. After solidification,
culture medium was added to each plate. Two weeks after plating, colo-
nies were visualized by using 0.4% iodonitrotetrazolium solution
(Sigma-Aldrich). Colonies were counted by light microscopy. The results
represent the average number of colonies per 35-mm plate.
Quantitative real-time PCR
RNA was extracted by using Trizol reagent (Invitrogen). cDNA was then
synthesized by reverse transcription of 1 lg of total RNA by using the
SuperScript VILO cDNA synthesis kit (Invitrogen). Quantitative real-time
PCR was performed by using MJ Opticon PCR analyser (MJ Research Inc.,
Waltham, MA, USA). The resulting cDNA was analysed by using the Taq-
man system for quantitative evaluation of specific transcripts according to
the manufacturer’s instructions (Applied Biosystems). All mRNA expression
data were normalized to 18S expression (Eukaryotic 18s rRNA endogenous
Control) in the corresponding sample. For the analysis, primers for prolifer-
ating cellular nuclear antigen (PCNA; Hs 00696862_m1) were obtained from
Applied Biosystems ‘Assays on Demand’ system (Applied Biosystem). PCR
reaction involved one cycle of 50°C for 2 min., one cycle of 95°C for
10 min. and 40 cycles of 95°C for 15 sec. and 60°C for 1 min. The results
were calculated by Ct (2DDCt) method.
Flow cytometric analysis of the cell cycle and S6
activation
Cells (~1 9 106), grown overnight without serum, were collected by
centrifugation, fixed with 70% ethanol overnight at 20°C, washed in
PBS and resuspended in 1 ml of staining solution (10 lg/ml propidium
iodide and 200 lg/ml RNase A in PBS with 0.04% Nonidet-P40). Sam-
ples were incubated overnight at 4°C in the dark. For the quantification
of S6 phosphorylation, cells (~2 9 106) were fixed with fixation buffer
(BD, Becton Dickinson Italia, Buccinasco, Milan, Italy) for 1 hr at 4°C,
washed and permeabilized with Perm/Wash buffer I (BD) for 1 hr at
room temperature, incubated with Alexa Fluor 647 anti-phospho-S6
(S235/S236; BD) for 1 hr at room temperature. Samples were analysed
with the flow cytometer Cytomics FC500 and analysis of cell cycle
phases was performed with the CXP 2.2 software (Beckman Coulter,
Milan, Italy).
ELISA
Quantification of IL-1a, IL-6, IL-1b and IL-8 in supernatant from LAM/
TSC cells was accomplished by Elisa in accordance with the manufac-
turer’s instructions (Invitrogen). LAM/TSC cells were incubated with
5-azacytidine (0.24 ng/ll), rapamycin (1 ng/ml) or anti-EGFR Ab3
(5 lg/ml), metilprednisolone (3.5 lg/ll; Sigma-Aldrich), repertaxin
(0.43 lg/ll; Sigma-Aldrich) or cycloheximide (10 lg/ml; Sigma-
Aldrich).
Statistical analysis
Data are expressed as mean  SD of n independent experiments.
Comparisons of three or more groups were performed by ANOVA, fol-
lowed by Bonferroni’s test. Comparison between two groups was per-
formed by Student’s t-test. P < 0.05 was considered statistically
significant.
Results
Proliferation of LAM/TSC cells is EGF-dependent
and anti-EGFR antibody causes cell death
From the chylous effusion of a patient affected by LAM associated
with TSC, we isolated a homogenous population (LAM/TSC cells)
positive to a-actin antibody, marker of smooth muscle cells, hamar-
tin, and the specific markers for TSC and LAM cells, HMB45 and
CD44v6 antibodies (Fig. 1A). Tuberin and its Thr1462-phosphory-
lated form were not expressed in LAM/TSC cells (Fig. 1A and B).
TSC2/meth and TSC2/ ASM cells were used as negative control,
for their absence of tuberin, and HASMCs as positive control. Pro-
liferation of LAM/TSC cells was EGF-dependent (Fig. 1C) as we pre-
viously reported also for TSC2/ and TSC2/meth ASM cells [16,
19, 25]. The exposure to two different anti-EGFR antibodies affected
LAM/TSC cell proliferation and caused their progressive death. The
antibody directed to the ligand binding site (clone 225: EGFR Ab3)
quickly blocked proliferation causing cell death within 2 weeks. Dif-
ferently, the antibody directed to the cell surface domain (clone
EGFR.1: EGFR Ab5) affected proliferation between 5 and 10 days
after exposure causing progressive cell death after 20 days of incu-
bation.
LAM/TSC cells do not express tuberin for an
epigenetic modification
Lymphangioleiomyomatosis/TSC cells bear a TSC2 germline mutation
on exon 21 (R750X-2251 C>T). Loss of heterozygosity was not
detectable by using a panel of microsatellite markers close to the
TSC2 locus on chromosome 16p13.3 (data not shown). As tuberin is
undetectable in LAM/TSC cells, we hypothesized that the presence of
an epigenetic defect underlying the silencing of the TSC2 wild-type
allele. It is well known that H3 lysine 9 methylation and CpG methyla-
tion may occur in heterochromatic regions and are associated with
silencing of gene expression, whereas the acetylation of histones H3
and H4, and H3 lysine 4 methylation correlate with euchromatin and
transcriptionally active genes [26]. Treatment of LAM/TSC cells with
trichostatin A, a histone deacetylase inhibitor, or 5-azacytidine that
inhibits CpG DNA methylation led to the expression of tuberin as con-
sequence of the chromatin remodelling (Fig. 2A). The positive effect
of 5-azacytidine on tuberin expression can be observed for up to
2 weeks following the incubation with the drugs (Fig. 2B). To assess
the epigenetic status of the TSC2 gene, by pyrosequencing assay, we
analysed DNA methylation of four regions that are considered the
exemplification of the entire TSC2 CpG islands (Fig. 2C). In this
region, we previously observed methylation associated with TSC2
silencing in cells derived from an AML of a TSC2 patient [16]. Both
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LAM/TSC cells and normal control show unmethylated patterns in all
the sequences studied (Fig. 2C). Nevertheless, the presence of tuber-
in appears to be related to a TSC2 epigenetic control, given that the
chromatin-remodelling treatments restore tuberin expression (Fig. 2A
and B). These findings suggest that the methylation of TSC2 CpG
islands is not a primary event in the TSC2 epigenetic regulation of
LAM/TSC cells. Therefore, we evaluated the TSC2 promoter chroma-
tin status by ChIP assay. We found an increase of repressed chroma-
tin signature (H3TrimK9) together with a reduction of open chromatin
markers (H3TrimK4 and H3Ac) in LAM/TSC cells compared with
HMECs (Fig. 2D). The TSC2 promoter chromatin structure in LAM/
TSC cells is consistent with tuberin-silenced status. After incubation
with 5-azacytidine, we observed a reduction of H3TrimK9 and an
increase of H3TrimK4 and H3Ac, indicating the opening of the TSC2
chromatin structure leading to expression of tuberin (Fig. 2D).
Rapamycin efficiently blocks proliferation of
LAM/TSC cells
Rapamycin significantly reduced proliferation either when it was
added at the medium at plating time or 3 hrs after plating, when the
cells were attached to the dish (Fig. 3A). These data differ from that
observed with TSC2/ and TSC2/meth ASM cells, where rapamycin
was mostly effective in reducing the proliferation only when adminis-
tered at plating time [19, 27]. Hyperphosphorylation of both p70S6K
and its ribosomal protein S6 substrate has been observed previously
in genetically modified cells lacking tuberin [28, 29]. Incubation with
anti-EGFR antibody and rapamycin reduced S6 phosphorylation with-
out affecting protein expression as quantitatively demonstrated by
densitometric analysis (Fig. 3B and Fig. S1). Erk phosphorylation
A
C
B
Fig. 1 Characterization of lymphangioleiomyomatosis/tuberous sclerosis complex (LAM/TSC) cells. (A) Cells are positive to a-actin (green labelling)
and negative to tuberin antibodies (red labelling; left panel), positive to HMB45 (green labelling) and negative to tuberin antibodies (red labelling;
middle panel), positive to CD44v6 (green labelling) and hamartin antibodies (red labelling; right panel). Nuclei are stained with DAPI (blue); scale
bars: 50 lm. (B) Representative immunoblots show tuberin and its phosphorylated form, and hamartin. b-actin was evaluated as loading control.
(C) Proliferation of LAM/TSC cells was evaluated up to 30 days in the presence of epidermal growth factor (EGF; 10 ng/ml) with EGF receptor
(EGFR) Ab3 (5 lg/ml), EGFR Ab5 (5 lg/ml) and without EGF. Error bars represent SD for four independent experiments.***P < 0.001 versus
control (ANOVA with Bonferroni’s test).
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Fig. 2 Lymphangioleiomyomatosi/tuberous sclerosis complex (LAM/TSC) cells do not express tuberin for an epigenetic modification. (A) Incubation
with trichostatin A (TSA) or 5-azacytidine (5-aza) promoted the expression of tuberin and phospho-tuberin in LAM/TSC cells, as evaluated by wes-
tern blotting. HASMCs were used as control. (B) Tuberin expression was evaluated after incubation with 5-aza for 20 days. MCF7 cells were used
as control. (C) Pyrosequencing analysis for CpG islands was performed in four regions without finding methylated pattern. (D) TSC2 promoter chro-
matin status was analysed by ChIP assay to study repressed chromatin (H3TrimK9 antibody) and open chromatin (H3TrimK4 and H3Ac antibodies)
in LAM/TSC cells and after incubation with 5-azacytidine. Human mammary epithelial cells were used as control. Error bars represent the SD for
n = 3.
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was also affected by the two agents, although rapamycin was effec-
tive only at the higher dose (Fig. 3B and Fig. S1). Erk expression was
unchanged (Fig. 3B and Fig. S1).
LAM/TSC cells spontaneously detach and grow
independently from anchorage
It has been described that the absence of tuberin in renal epithelial
tumour cell lines from Eker rats leads to reduction of both adhesion
and formation of aggregates [30]. We observed that LAM/TSC cells
can spontaneously detach from the sub-confluent monolayer and
grow for some time in suspension, then re-attach to the plate and
grow in monolayer again (Fig. 4A). The majority of the non-adher-
ent LAM/TSC cells were viable (Fig. 4B). About 10% of LAM/TSC
cells were floating after 24 hrs of culture (Fig. 4C), while the per-
centage was slightly higher (17%) after incubation with 5-azacyti-
dine for 96 hrs (ns versus non-adherent control cells) likely
because of a cytotoxic effect of the chromatin-remodelling agent.
In fact, 5-azacytidine reduced significantly the viability of non-
adherent cells compared with non-adherent untreated cells without
any effect on the viability of adherent cells (Fig. 4D). Tuberin was
not expressed either in adherent and non-adherent LAM/TSC cells
(Fig. 4E). LAM/TSC cells survived and grew when cultured in soft
agar, where they formed colonies, indicating their loss of contact
inhibition and anchorage-independent survival (Fig. 4F). Differently,
HASMCs failed to form colonies in soft agar, showing an adhe-
sion-dependent growth.
Focal adhesion kinase (FAK) is a non-receptor cytosolic kinase
concentrated in focal contacts and probably involved in regulation of
migration and survival mediated by contact with extracellular matrix
protein [31]. Phosphorylation of FAK was reduced in non-adherent
LAM/TSC cells compared with adherent cells (Fig. 4G). A similar
result was observed for Akt, S6 and mammalian target of rapamycin
(mTOR) phosphorylation. The low S6 phosphorylation of non-adher-
ent cells was confirmed also by flow cytometric analysis
(13.31  3.95%; P < 0.01 versus adherent cells), while positivity
was high (82.3  2.47%) in adherent cells. To evaluate if the loss of
contact in non-adherent LAM/TSC cells might be the event causing
the inhibition of FAK/Akt pathway, adherent LAM/TSC cells were incu-
bated with PF228, a FAK inhibitor. FAK phosphorylation was signifi-
cantly reduced by 5 ng/ll of PF228 and slightly affected at the dose
of 0.5 ng/ll (Fig. 4G and Fig. S2). FAK is an upstream regulator of
Akt signalling pathway and FAK-Akt interaction is particularly critical
for metastatic adhesion [32]. In LAM/TSC cells, FAK inhibition caused
the reduction of Akt phosphorylation, which was followed by inhibi-
tion of phosphorylation and autophosphorylation of mTOR, and con-
sequently by a strong reduction of S6 phosphorylation as it occurs in
non-adherent cells (Fig. 4G). By densitometric analysis, PF228 (5 ng/
ll) caused a statistically significant inhibition of the phosphorylation
of Akt, mTOR and S6 compared with adherent control cells (Fig. S2).
These data suggest that LAM/TSC cell detachment might control
phosphoinositide 3-kinase (PI3K)/mTOR pathway through FAK. In
cells that survive and proliferate attached to the dish, such as HAS-
MCs, TSC2/ and TSC2/meth ASM cells, as expected, phosphoryla-
tion of FAK, Akt, mTOR and S6 was significantly reduced by PF228
(5 ng/ll), suggesting that LAM/TSC cells detach from the dish for the
inhibition of FAK/Akt/mTOR pathway, but this event does not appear
to be related to TSC2 alterations (Fig. S3A and B). Rapamycin and
anti-EGFR antibodies affected the viability of non-adherent LAM/TSC
A B
Fig. 3 Rapamycin inhibits proliferation of lymphangioleiomyomatosis/tuberous sclerosis complex (LAM/TSC) cells. (A) Proliferation was evaluated
after incubation with rapamycin (R) at plating time (at plt) at the concentration of 1 ng/ml (1) or 5 ng/ml (5) or 3 hrs after plating (3 h). Error bars
represent SD for four independent experiments. Error bars represent SD for four independent experiments.**P < 0.01 and ***P < 0.001 versus
control (ANOVA followed by Bonferroni’s test).(B). Phospho-S6 and S6, phospho-Erk and Erk levels were evaluated following incubation with rapamy-
cin and EGF receptor Ab3 for 6 days 3 hrs after plating. b-actin was evaluated as loading control.
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Fig. 4 Lymphangioleiomyomatosis/tuberous sclerosis complex (LAM/TSC) cells survive in adherent (A) and non-adherent (NA) status independently
from anchorage. (A) Representative microscopy images with LAM/TSC cells that detach (arrows) from the dish in subconfluent and confluent con-
dition (left and right panel, respectively). (B) Viability of NA LAM/TSC cells, analysed by Trypan blue assay, is expressed as percentage of dead or
viable NA LAM/TSC cells. Error bars represent the SD for three independent experiments. Unpaired Student’s t-test p-values: **P < 0.01 versus
dead cells. (C) The percentage of NA and A LAM/TSC cells was evaluated in control cells and after incubation with 5-azacytidine (5-aza). Error bars
represent the SD for three independent experiments. Unpaired Student’s t-test p-values: ***P < 0.001 versus A cells. (D) Viability of A and NA
LAM/TSC cells was analysed in control cells and after incubation with 5-aza. Error bars represent the SD for three independent experiments.
Unpaired Student’s t-test p-values: *P < 0.05 and **P < 0.01 versus A LAM/TSC cells; #P < 0.05 versus control NA LAM/TSC cells. (E) Evaluation
of tuberin expression in A, NA LAM/TSC cells and human aortic smooth muscle cells (HASMCs) used as control. b-actin is the loading control. (F)
Representative colony formation in soft agar of LAM/TSC cells and HASMCs, used as control, assessed 2 weeks after plating to test anchorage-
independent survival (magnification 20 9 ). Graph indicates number of LAM/TSC cell colonies compared with colonies of HASMCs. Error bars rep-
resent the SD for three independent experiments. Unpaired Student’s t-test p-values: **P < 0.01 versus HASMCs colonies. (G) Phospho-focal
adhesion kinase, phospho-Akt, phospho-mTOR (Ser 2448), phospho-mTOR (Ser2481) and phospho-S6 in A and NA LAM/TSC cells and after incu-
bation with PF228 (0.5 or 5 ng/ll). b-actin was evaluated as loading control. (H) The percentage of viable NA and (I) viable A cells was evaluated
by trypan blue assay after 24 hrs of incubation with rapamycin (R) at the concentration of 1 (1) or 5 (5) ng/ml, and anti-EGF receptor (EGFR) anti-
bodies (EGFR Ab3 and EGFR Ab5). Error bars represent the SD for three independent experiments. ***P < 0.001 versus control cells (ANOVA fol-
lowed by Bonferroni’s test).
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cells, while the drugs did not have any statistically significant effect in
adherent cells (Fig. 4H and I).
Replication of LAM/TSC cells is lower in non-
adherent than in adherent condition
For reasons of the different extent of S6 phosphorylation in adherent
and non-adherent cells, and the S6 role in the process of growth, we
evaluated the proliferative status of LAM/TSC cells by flow cytometric
analysis. We found that most adherent cells were in high replication
condition with a higher DNA replication phase S compared with non-
adherent LAM/TSC cells and HASMCs used as control (Fig. 5A). The
floating cells were less in G0/G1 phase than adherent cells. The num-
ber of apoptotic cells in any group was low. To better analyse the rep-
lication of adherent and non-adherent LAM/TSC cells, we evaluated
specific cyclin-dependent kinases (Cdks), such as Cdk 4, Cdk2 and
Cdk6, which control the transition from G1 to the S phase of the cell
cycle, by combining with their appropriate cyclin D [33]. Deregulation
of Cdk4 and cyclin D1 is widespread in human cancer. The expression
of Cdk4 and cyclin D1 is decreased in non-adherent LAM/TSC cells
compared with the adherent cells (Fig. 5B). Moreover, we analysed
PCNA, essential for DNA replication and repair of DNA errors, highly
expressed during G1 and S-phases that decrease in G2 and M-phases
[34]. Proliferating cellular nuclear antigen protein level and mRNA
expression were significantly reduced in non-adherent LAM/TSC cells
compared with adherent cells (Fig. 5B and C).
LAM/TSC cells express EMT features
One of the steps driving EMT is the repression of E-cadherin, result-
ing in the loss of cell–cell adhesion. According to Barnes et al. [30],
the loss of tuberin in the Eker rat-derived cells leads to a significant
reduction in membrane E-cadherin. Adherent and non-adherent LAM/
TSC cells did not express E-cadherin, while vimentin, marker of mes-
enchymal cells, was detected (Fig. 6A). SNAIL, a transcription factor
regulating E-cadherin expression and marker of epithelial mesenchy-
mal transition, was identified by western blotting in LAM/TSC cells as
it occurs in COS7 cells used as control (Fig. 6B). When tuberin
expression was induced by exposure to 5-azacytidine, LAM/TSC cells
were positively labelled by E-cadherin antibody in plasma membrane
and cytoplasm (Fig. 6C). These observations support the concept that
tuberin expression modulates the EMT features of LAM/TSC cells also
in human TSC2 cells.
LAM/TSC cells secrete IL-6 and IL-8
Tumour cells migrate from mouse primary tumours through a pro-
cess of EMT, and this process is dependent on an inflammatory
microenvironment [20]. Likewise, IL-6 promotes EMT in breast can-
cer cells, and SNAIL can induce IL-6 expression in keratinocytes [35,
36]. Interleukin-8 and IL-6 production is regulated by PI3K and mito-
gen-activated protein kinase pathways, which are also involved in
TSC cell deregulated functions [37–39]. Interleukin-1a, IL-6 and IL-8
were secreted by LAM/TSC cells as the inhibition of protein biosyn-
thesis by incubation with cycloheximide prevented their secretion
(Fig. 7A–C). The release of the interleukins was, however, not signifi-
cantly affected by rapamycin or anti-EGFR antibody exposure. Inter-
leukin-6, IL-8 and IL-1a secretion was inhibited by the incubation
with 5-azacytidine leading to tuberin expression (Fig. 7D–F).
As expected, methylprednisolone and repertaxin, an antagonist of
IL-8 receptor, effectively reduced the release of interleukins [40]
(Fig. 7A–C). Interleukin-1b was not detectable.
Discussion
The loss of TSC2 function leads to a spectrum of diseases that under-
lie abnormalities in cell growth, proliferation, differentiation and
migration [41]. Despite the extensive biochemical and molecular
characterization of TSC1/TSC2 pathway, the mechanisms linking
these findings to the phenotype remain, however, quite not under-
stood. Tuberous sclerosis complex is a tumour-suppressor gene syn-
drome associated with benign and, more rarely, malignant tumours.
In this study, we describe the characterization of ASM cells derived
from chylous effusion of a patient affected by LAM associated with
TSC. LAM/TSC cells are positive for the LAM and TSC markers,
CD44v6 and HMB45 antibody. The reactivity of LAM/TSC cells with
HMB45 antibody was heterogeneous, as previously reported for
other TSC and LAM cells [16, 27, 42]. The difference in HMB45
positivity has been related to the expression of tuberin and to the
progression of LAM. LAM/TSC cells bear a germline mutation in
exon 21 of TSC2 and do not express tuberin because of an epige-
netic silencing of the TSC2 second allele that confirms our previ-
ously published evidence that an epigenetic alteration of TSC2 can
cause the loss of tuberin in TSC cells [16]. The process of inactiva-
tion of tumour suppressor genes by DNA methylation at CpG dinu-
cleotides is common in human cancers and results in the loss of
gene functions [18, 43]. Recent developments in cancer research
have shown that epigenome modifications are significantly associ-
ated with the development and progression of tumours. In our
LAM/TSC cells, no methylated CpGs were detected, although the
entire TSC2 CpG island had been screened for DNA methylation by
pyrosequencing analysis. However, we found histone modifications
characterizing closed chromatin domains in the TSC2 control region
and tuberin expression after chromatin-remodelling agent treat-
ment, thus the loss of tuberin is associated with epigenetic silenc-
ing of the TSC2 gene, as observed in TSC2/meth ASM cells. The
epigenetic regulation of gene expression is a very complex and
multifactorial process in which a different combination of histone
modifications and DNA methylation can be observed far or near
inactivated genes [44]. In the light of this considerations, our find-
ings in TSC2/meth ASM cells [16] and LAM/TSC cells indicate that
different epigenetic signatures related to closed chromatin confor-
mation can affect TSC2 and may be crucial in the development of
TSC lesions because they lead to the absence of tuberin expression
as it is caused by the deletion of the wild-type allele in TSC2/
ASM cells. A better comprehension of the aberrant epigenetic
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events occurring in LAM/TSC cells may be useful in the develop-
ment of more effective therapeutic interventions also based on
chromatin-remodelling agents aimed at the epigenetic silencing
relief of the TSC2 [16, 45].
The LAM/TSC cells display the physiological ability to survive in
adherent and non-adherent status with no expression of tuberin in
both conditions. The process is apparently highly correlated with
changes in FAK activity that is high in adherent cells, as expected for
cells preparing to migrate, and low in non-adherent cells [31]. FAK is
an upstream regulator of the Akt signalling pathway in various cancer
cell lines and xenograft tumour models to potentiate proliferation,
migration and cell survival [46]. Focal adhesion kinase inactivation in
A
B C
Fig. 5 Proliferation of lymphangioleiomyomatosis/tuberous sclerosis complex (LAM/TSC) cells in non-adherent status and adherent condition. (A) Ex-
emplificative linear fluorescence histograms of PI of different phases of cell cycle were analysed by flow cytometric analysis in human aortic smooth
muscle cells (HASMCs,) non-adherent (NA) and adherent (A) LAM/TSC cells. Abscissa indicates relative intensity of PI fluorescence and ordinate rel-
ative number of cells. Data are expressed as mean  SD of three independent experiments. **P < 0.01 and ***P < 0.001 versus HASMCs;
##P < 0.01 versus A LAM/TSC cells (ANOVA followed by Bonferroni’s test). (B) Representative western blots show proliferating cellular nuclear anti-
gen (PCNA), Cdk4 and cyclin D-1 expression in A and NA LAM/TSC using HASMCs as control. b-actin is the loading control. Relative intensity by
densitometric analysis was evaluated relatively to b-actin levels. Error bars represent the SD for four experiments. *P < 0.05 versus HASMCs (ANOVA
with Bonferroni’s test). (C) PCNA mRna relative expression was analysed by RT-PCR in A and NA LAM/TSC cells considering HASMCs value as 1
unit. Error bars represent the SD for three experiments. Unpaired Student’s t-test p-values: *P < 0.05 versus HASMCs.
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non-adherent LAM/TSC cells leads to reduced activation of Akt,
mTOR and S6. So the observed transient impairment of S6 phosphor-
ylation might be related to the cell detachment, which is accompanied
by the inhibition of FAK. The different status of S6 phosphorylation in
adherent and non-adherent cells is consistent with the replication rate
data, which is high in adherent LAM/TSC cells and very low in non-
adherent cells. The impaired G1/S phase progression is a general fea-
ture of cells that have undergone EMT [47]. G1/S phase progression
is reduced in non-adherent LAM/TSC cells, as it occurs for the
expression of the markers of proliferation, suggesting that the
reduced proliferation may favour the mobility of the cells in this con-
dition. It was recently shown that the lack of plasma membrane E-
cadherin in Tsc2 (/) mutant cells might be related to their reduced
adhesive ability compared with the cells expressing tuberin, and this
may lead to detachment and growth in suspension [30]. Epithelial-to-
mesenchymal transition is an important event that endows cells with
A B C
Fig. 6 Lymphangioleiomyomatosis/tuberous sclerosis complex (LAM/TSC) cells express epithelial-to-mesenchymal transition marker. (A) Evaluation
of E-cadherin and vimentin expression in non-adherent (NA) and adherent (A) LAM/TSC cells. MCF7 cells were used as control. b-actin is the load-
ing control. (B) SNAIL is present in A and NA LAM/TSC cells such as in COS7 cells used as control. b-actin was the loading control. (C) Represen-
tative immunofluorescence microscopy images of E-cadherin staining (green labelling), tuberin expression (red labelling) in control LAM/TSC cells
and after 5-azacytidine (5-aza) exposure. Nuclei were stained with DAPI (blue); scale bars: 75 lm.
A B C
D E F
Fig. 7 Lymphangioleiomyomatosis/tuberous sclerosis complex (LAM/TSC) cells secrete interleukins. (A) IL-6 (B) IL-8 and (C) IL-1a secretion were
evaluated by Elisa in control LAM/TSC cells and after cycloheximide (CHX) overnight incubation. The effect of anti-EGF receptor (EGFR) antibody
(EGFR Ab3), rapamycin (R1), methylprednisolone (MP) and repertaxin (Rep) after 48 hrs of incubation was evaluated. **P < 0.01 and
***P < 0.001 versus control LAM/TSC cells (ANOVA followed by Bonferroni’s test). (D) IL-6 (E) IL-8 and (F) IL-1a release was evaluated after 5-aza-
cytidine (5-aza) incubation. Error bars represent the SD for three experiments. Unpaired Student’s t-test p-values: *P < 0.05 versus control LAM/
TSC cells.
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migratory and invasive properties inducing the invasive phenotype,
and can represent the molecular base through which the TSC2 cells
are able to migrate as proposed in the benign ‘metastatic’ theory of
LAM [48]. The presence of mesenchymal tumours in the kidneys of
patients affected by TSC suggests that hamartin and tuberin could
regulate differentiation of an early renal precursor cell involved in
TSC angiomyolipoma pathogenesis [49]. We observed that LAM/TSC
cells display anchorage-independent growth and mesenchymal fea-
tures. These EMT characteristics are dependent upon tuberin expres-
sion in LAM/TSC cells, as it had been shown in Tsc2(/) Eker rat
cell lines [30]. Epithelial-to-mesenchymal transition is accompanied
by loss of cell–cell contacts, characterized by a down-regulation of
E-cadherin expression [30]. Also, the inflammatory microenviron-
ment may represent an important factor in the regulation of carci-
noma cell migration from primary tumours through a process of
EMT [20]. Likewise, IL-6 promotes EMT in breast cancer cells, and
SNAIL can induce IL-6 expression [35, 36]. Lymphangioleiomyoma-
tosis/TSC cells secrete, probably in a tuberin-dependent manner,
high amounts of IL-6 and IL-8 that cannot be significantly affected
by the exposure to rapamycin or anti-EGFR antibodies. These data
suggest that the mechanisms regulating interleukin production in
LAM/TSC cells are dependent on the activity of pathways sensitive
to tuberin.
The proliferation of LAM/TSC cells is EGF-dependent and the
blockade of EGFR causes cell death as we had previously reported
for TSC2/meth and TSC2/ ASM cells [16, 19, 27]. The action of
the two used antibodies is ranging from immediate cell death to
delayed cytotoxic/cytostatic reactions. Both anti-EGFR monoclonal
antibodies prevent ligand binding and interrupt EGF signalling cas-
cade; these data suggest that anti-EGFR antibody-Ab5 interaction
may have some kind of early positive effects on LAM/TSC cells
before becoming toxic. In LAM/TSC cells, rapamycin-mediated inhi-
bition of mTOR causes the blocking of proliferation either when
rapamycin was added at plating time or 3 hrs after plating; differ-
ently in TSC2/ and TSC2/meth ASM cells, rapamycin was effica-
cious only when added at plating time. The efficacy of rapamycin
in LAM/TSC cells might be secondary to their specific ability to
survive independently from the anchorage as demonstrated by the
reduced viability of non-adherent cells after the drug incubation.
These data confirmed the recent published findings, demonstrating
the ability of Sirolimus to decrease the number of circulating LAM
cells in blood and urine of LAM patients [50]. Together, all these
data suggest that a valid pharmacological therapy for LAM/TSC
cells has to control both proliferation and migration.
In conclusion, the current study confirmed that an epigenetic
event may be rather common in LAM or TSC cells leading to impaired
transcription of tuberin with a full deployment of TSC cellular pheno-
type. The chromatin-remodelling agents, triggering the tuberin tran-
scription, can revert the mesenchymal features such as E-cadherin
expression and block interleukins secretion. In addition, the LAM/TSC
cells display the ability to survive independently from anchorage
acquiring invasive characteristics. Rapamycin and anti-EGFR anti-
bodies are capable of affecting the survival of non-adherent LAM
cells.
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Figure S1 Densitometric analysis of protein levels of phospho-S6,
S6, phospho-Erk, Erk was evaluated by western blotting (Fig. 3B) fol-
lowing incubation with rapamycin and EGFR Ab3 for 6 days 3 hrs
after plating. Densitometric analysis was evaluated relatively to
b-actin levels. Error bars represent the SD for four independent
experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus control
(ANOVA with Bonferroni’s test).
Figure S2 Densitometric analysis of protein levels of phospho-FAK,
phospho-Akt, phospho-mTOR (Ser 2448), phospho-mTOR (Ser2481)
and phospho-S6 was evaluated by western blotting (Fig. 4G) in A and
NA LAM/TSC cells and after incubation with PF228 (1 or 10 lM).
Densitometric analysis was measured relatively to b-actin levels.
Error bars represent the SD for four independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001 versus A cells (ANOVA with Bon-
ferroni’s test).
Figure S3 (A) Levels of phospho-FAK, phospho-Akt, phospho-mTOR
(Ser 2448), phospho-mTOR (Ser2481) and phospho-S6 (representa-
tive experiments) were evaluated by western blotting in TSC2/meth,
TSC2/ ASM cells and in HASMCs after incubation with PF573228
(PF228; 1 or 10 lM). b-actin was evaluated as loading control. (B)
Relative intensity by densitometric analysis was measured relatively
to b-actin levels. Error bars represent the SD for four independent
experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus control of
each group (ANOVA with Bonferroni’s test).
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